||
OliX Pharmaceuticals (226950.KQ) has confirmed a visceral fat reduction effect in preclinical results for its obesity drug candidate. Ahead of entering clinical trials next year, the company plans to use the findings as key evidence in discussions with global pharmaceutical companies on joint development and technology transfer
OliX said on the 30th that its analysis of visceral fat changes at 49 days after administration of its obesity drug “OLX501A” showed that the OLX501A group’s visceral fat decreased by 29.2%, based on baseline and food intake adjustments. The visceral fat reduction rate in the competing candidate group was 10.0%, confirming OLX501A’s efficacy. Over the same period, the control group saw an increase of 11.1%
The study was conducted to directly compare the efficacy of OLX501A and a global competing candidate under identical conditions in obese monkeys selected based on body weight and body fat. Both substances were administered twice in total at a dose of 3 mg/kg, spaced one month apart. Target gene suppression rates, visceral fat changes, and pharmacodynamic biomarkers were evaluated
Unlike existing treatments that suppress appetite, OLX501A has a mechanism that directly regulates the ALK7 pathway within fat cells to promote fat breakdown. According to the company, it can selectively reduce body fat, including visceral fat, without relying heavily on changes in food intake. The ALK7 target gene suppression rate of OLX501A, measured in subcutaneous fat at 70 days after administration, was approximately 90%, a level similar to the competing candidate. OLX501A is based on a fat tissue-targeting small interfering RNA (siRNA) platform developed by OliX.
Pharmacodynamic biomarker analysis also confirmed differentiated activity compared to the competing candidate. According to OliX, the expression of ADRB3, a downstream functional biomarker that increases when ALK7 is suppressed, was approximately twice as high in the OLX501A group compared to the competing candidate at 28 days after administration, and a higher expression level was maintained at 70 days after administration
Lee Dong-ki, CEO of OliX, stressed, “OLX501A is being developed as an obesity treatment aimed at improving body composition in the direction of selectively reducing body fat while preserving muscle mass as much as possible.” He added, “We will push ahead with development without setbacks, targeting the submission of an investigational new drug plan in the first half of next year.”
#OliX#ObesityDrug#OLX501A#siRNA#Biotech#KoreaPharma#Preclinical
Original reporting by Han Tae-hee for Seoul Economic Daily
AI-translated from Korean. Quotes from foreignxact original wording
View Korean originalTranslation Policy
More →
Most Read This Week
1-5
- 1Spouses of Dementia Patients Face 70% Higher Risk, Study Finds
- 2Typhoon Dolphin Heads North Toward Japan After Magnitude 7.1 Quake
- 3Samsung, Broadcom Sign $200 Billion Chip Supply Deal, Presidential Office Says
- 4Toyota’s Best-Selling RAV4 Grows Stronger with PHEV Powertrain
- 5KOSPI Reclaims 7,000 on Chip Stock Strength
← Back to Home
